Method for treating pruritus comprising administering an NR10 antagonist
US8431127B2 · kind B2 · utility
9Cited by
8References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 5, 2008 |
| Grant date | Apr 30, 2013 |
| Priority date | — |
| Expiry date | Dec 5, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present inventors isolated clone BM095 from a human antibody phage library, which had a strong growth inhibitory activity in the IL-31-dependent Ba/F3 cell growth assay system. When administered to pruritus model mice, the anti-mouse NR10 neutralizing antibody exhibited a marked symptom-suppressing effect. Thus, it was revealed that anti-NR10 neutralizing antibodies are useful as therapeutic agents for pruritus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.